Upfront Payments & License Fees, Prior Period was Lakefront Biotherapeutics’s largest revenue line in fiscal 2017, bringing in $71.97M of $186.89M (39%).
| Retrospective application and retrospective restatement [axis] | FY 2017 |
|---|---|
| Upfront Payments & License Fees, Prior Period | $71.97M |
| Collaboration Agreement For Filgotinib, Upfront Payment, Prior Period | $62.49M |
| Collaboration Agreement For Cf, Milestone Payments, Prior Period | $33.60M |
| Collaboration Agreement For Filgotinib, Milestone Payments, Prior Period | $9.35M |
| Collaboration Agreement For Filgotinib, Subscription Agreement, Prior Period | $8.85M |
| Collaboration Agreement For Osteoarthritis, License Fee, Prior Period | $638.00K |
| Total | $186.89M |
Lakefront Biotherapeutics brought in $186.89M from its six revenue lines in fiscal 2017, the year ended December 31, 2017. Upfront Payments & License Fees, Prior Period was the largest at $71.97M (38.5%), ahead of Collaboration Agreement For Filgotinib, Upfront Payment, Prior Period at $62.49M (33.4%) and Collaboration Agreement For Cf, Milestone Payments, Prior Period at $33.60M (18.0%). The other three revenue lines brought in $18.84M combined.
Research & Development was Lakefront Biotherapeutics’s largest segment in fiscal 2016, bringing in $121.62M of $129.52M (94%).
| Segments [axis] | FY 2016 |
|---|---|
| Research & Development | $121.62M |
| Fee For Services | $7.90M |
| Total | $129.52M |
Lakefront Biotherapeutics brought in $129.52M from its two segments in fiscal 2016, the year ended December 31, 2016. Research & Development was the largest at $121.62M (93.9%), ahead of Fee For Services at $7.90M (6.1%).
Galapagos Nv (Belguim) was Lakefront Biotherapeutics’s largest revenue line in fiscal 2016, bringing in $121.70M of $129.52M (94%).
| Subsidiaries [axis] | FY 2016 |
|---|---|
| Galapagos Nv (Belguim) | $121.70M |
| Fidelta D.O.O. (Croatia) | $7.73M |
| Galapagos Sasu (France) | $84.00K |
| Total | $129.52M |
Lakefront Biotherapeutics brought in $129.52M from its three revenue lines in fiscal 2016, the year ended December 31, 2016. Galapagos Nv (Belguim) was the largest at $121.70M (94.0%), ahead of Fidelta D.O.O. (Croatia) at $7.73M (6.0%) and Galapagos Sasu (France) at $84.00K (0.1%).
Lakefront Biotherapeutics (LKFT) reports its revenue by retrospective application and retrospective restatement [axis], by segments [axis] and by subsidiaries [axis]. In fiscal 2017, Upfront Payments & License Fees, Prior Period was its largest revenue line, bringing in $71.97M (38.5% of the total), followed by Collaboration Agreement For Filgotinib, Upfront Payment, Prior Period at $62.49M (33.4%).
Upfront Payments & License Fees, Prior Period was Lakefront Biotherapeutics' largest revenue line in fiscal 2017, bringing in $71.97M, or 38.5% of the $186.89M total across its six revenue lines.
Research & Development was Lakefront Biotherapeutics' largest segment in fiscal 2016, bringing in $121.62M, or 93.9% of the $129.52M total across its two segments.
Every figure comes from Lakefront Biotherapeutics' annual financial filings, as reported. Each line keeps the name Lakefront Biotherapeutics gives it, and years follow its fiscal calendar.
Lakefront Biotherapeutics' revenue by retrospective application and retrospective restatement [axis] goes back to fiscal 2017, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.